Skip to main content
SpringerLink
Log in

Doxorubicin

  • Chapter
Extravasation of Cytotoxic Agents

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Original articles

  1. Bhawan J, Petry J, Rybak ME: Histologic changes induced in skin by extravasation of doxorubicin (adriamycin). J Cutan Pathol 16: 158–163, 1989.

    Article  PubMed  CAS  Google Scholar 

  2. Bowers DG, Lynch JB: Adriamycin extravasation. Plast Reconstr Surg 61: 86–92, 1978.

    Article  PubMed  Google Scholar 

  3. Köstering H, Kasten U, Ruskowski H, et al: Lokale Toxizität des Adriamycins. In: Füllenbach D, et al (eds) Beiträge zur Onkologie. S. Karger 9: 76–93, 1981.

    Google Scholar 

  4. Larson DL: What is the appropriate management of tissue extravasation by antitumor agents? Plast Reconstr Surg 75: 397–402, 1985.

    Article  PubMed  CAS  Google Scholar 

  5. Reilly JJ, Neifeld JP, Rosenberg SA: Clinical course and management of accidental adriamycin extravasation. Cancer 40: 2053–2056, 1977.

    Article  PubMed  CAS  Google Scholar 

  6. Rudolph R, Stein RS, Pattillo RA: Skin ulcers due to adriamycin. Cancer 38: 1087–1094, 1976.

    Article  PubMed  CAS  Google Scholar 

  7. Linder RM, Upton J, Osteen R: Management of extensive doxorubicin hydrochloride extravasation injuries. J Hand Surg 8: 32–38, 1983.

    CAS  Google Scholar 

  8. Rudolph R: Ulcers of the hand and wrist caused by doxorubicin hydrochloride. Orthop Rev 7: 93–95, 1978.

    Google Scholar 

  9. Lauvin R, Miglianico L, Hellegouarc’h H: Skin cancer occurring 10 years after the extravasation of doxorubicin. N Engl J Med 332: 754, 1995.

    Article  PubMed  CAS  Google Scholar 

  10. Lawrence HJ, Walsh D, Zapotowski KA, et al: Topical dimethylsulfoxide may prevent tissue damage from anthracycline extravasation. Cancer Chemother Pharmacol 23: 316–318, 1989.

    Article  PubMed  CAS  Google Scholar 

  11. Tsavaris NB, Karagiaouris P, Tzannou I, et al: Conservative approach to the treatment of chemotherapy-induced extravasation. J Dermatol Surg On-col 16: 519–522, 1990.

    CAS  Google Scholar 

  12. Tsavaris NB, Komitsopoulou P, Karagiaouris P, et al: Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach. Cancer Chemother Pharmacol 30: 330–333, 1992.

    Article  PubMed  CAS  Google Scholar 

  13. Comas D, Mateu J: Treatment of extravasation of both doxorubicin and vincristine administration in a y-site infusion. Ann Pharmacother 30: 244–246, 1996.

    PubMed  CAS  Google Scholar 

  14. Ludwig CU, Stoll HR, Obrist R, et al: Prevention of cytotoxic drug induced skin ulcers with dimethyl sulfoxide (DMSO) and a-tocopherole. Eur J Cancer Clin Oncol 23: 327–329, 1987.

    Article  PubMed  CAS  Google Scholar 

  15. Bertelli G, Dini D, Forno G, et al: Dimethylsulphoxide and cooling after extravasation of antitumour agents. Lancet 341: 1098–1099, 1993.

    Article  PubMed  CAS  Google Scholar 

  16. Bertelli G, Gozza A, Forno GB, et al: Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 13: 2851–2855, 1995.

    PubMed  CAS  Google Scholar 

  17. Olver IN, Schwarz MA: Use of dimethyl sulfoxide in limiting tissue damage caused by extravasation of doxorubicin. Cancer Treat Rep 67: 407–408, 1983.

    PubMed  CAS  Google Scholar 

  18. Olver IN, Aisner J, Hament A, et al: A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol 6: 1732–1735, 1988.

    PubMed  CAS  Google Scholar 

  19. Zweig JI, Kabakow B: An apparently effective countermeasure for doxorubicin extravasation. JAMA 239: 2116, 1978.

    Article  PubMed  CAS  Google Scholar 

  20. Scuderi N, Onesti MG: Antitumor agents: extravasation, management, and surgical treatment. Ann Plast Surg 32: 39–44, 1994.

    Article  PubMed  CAS  Google Scholar 

  21. Heckler FR: Current thoughts of extravasation injuries. Clin Plast Surg 16: 557–563, 1989.

    PubMed  CAS  Google Scholar 

  22. Jackson IT, Robinson DW: Severe tissue damage following accidental subcutaneous infusion of bicarbonate solution. Scot Med J 21: 200–201, 1976.

    PubMed  CAS  Google Scholar 

  23. Gaze NR: Tissue necrosis caused by commonly used intravenous infusions. Lancet 2: 417–419, 1978.

    Article  PubMed  CAS  Google Scholar 

  24. Kappel B, Hindenburg AA, Taub RN: Treatment of anthracycline extravasation — a warning against the use of sodium bicarbonate. J Clin Oncol 5: 825–826, 1987.

    PubMed  CAS  Google Scholar 

  25. Cohen MH: Amelioration of adriamycin skin necrosis: an experimental study. Cancer Treat Rep 63: 1003–1004, 1979.

    PubMed  CAS  Google Scholar 

  26. Luedke DW, Kennedy PS, Rietschel RL: Histopathogenesis of skin and subcutaneous injury induced by adriamycin. Plast Reconstr Surg 63: 463–465, 1979.

    Article  PubMed  CAS  Google Scholar 

  27. Dorr RT, Alberts DS, Chen HS: The limited role of corticosteroids in ameliorating experimental doxorubicin skin toxicity in the mouse. Cancer Chemother Pharmacol 5: 17–20, 1980.

    Article  PubMed  CAS  Google Scholar 

  28. Coleman JJ, Walker AP, Didolkar MS: Treatment of adriamycin-induced skin ulcers: a prospective controlled study. J Surg Oncol 22: 129–135, 1983.

    Article  PubMed  CAS  Google Scholar 

  29. Petro JA, Graham WP, Miller SH, et al: Experimental and clinical studies of ulcers induced with adriamycin. Surg Forum 30: 535–537, 1979.

    PubMed  CAS  Google Scholar 

  30. Cohen SC, DiBella NJ, Michalak JC: Recall injury from adriamycin. Ann Intern Med 83: 232, 1975.

    Article  PubMed  CAS  Google Scholar 

  31. Etcubanas E, Wilbur JR: Uncommon side effects of adriamycin (NSC123127). Cancer Chemother Rep 58: 757–758, 1974.

    PubMed  CAS  Google Scholar 

  32. Ostrowski MJ: An unusual allergic reaction in a vein following intravenous adriamycin. Clin Oncol 2: 179–180, 1976.

    PubMed  CAS  Google Scholar 

  33. Souhami L, Feld R: Urticaria following intravenous doxorubicin administration. JAMA 240: 1624–1626, 1978.

    Article  PubMed  CAS  Google Scholar 

  34. Dorr RT, Alberts DS: Pharmacologic antidotes to experimental doxorubicin skin toxicity: a suggested role for beta-adrenergic compounds. Cancer Treat Rep 65: 1001–1006, 1981.

    PubMed  CAS  Google Scholar 

  35. Sonneveld P, Wassenaar HA, Nooter K: Long persistence of doxorubicin in human skin after extravasation. Cancer Treat Rep 68: 895–896, 1984.

    PubMed  CAS  Google Scholar 

  36. Pitkänen J, Asko-Seljavaara S, Gröhn P, et al: Adriamycin extravasation: surgical treatment and possible prevention of skin and soft-tissue injuries. J Surg Oncol 23: 259–262, 1983.

    Article  PubMed  Google Scholar 

  37. Barlock AL, Howser DM, Hubbard SM: Nursing management of adriamycin extravasation. Am J Nurs 79: 94–96, 1979.

    PubMed  CAS  Google Scholar 

  38. Germain BS, Houlihan N, D’Amato S: Dimethyl sulfoxide therapy in the treatment of vesicant extravasation. J Intrav Nurs 17: 261–266, 1994.

    Google Scholar 

  39. Bartkowski-Dodds L, Daniels JR: Use of sodium bicarbonate as a means of ameliorating doxorubicin-induced dermal necrosis in rats. Cancer Chemother Pharmacol 4: 179–181, 1980.

    Article  PubMed  CAS  Google Scholar 

  40. Harwood K, Gonin R: Short term vs. long term local cooling after doxorubicin (DOX) extravasation: an eastern cooperative oncology group (ECOG) study. Proc ASCO 13: 447 (abstract 1544), 1994.

    Google Scholar 

  41. Nobbs P, Barr RD: Soft-tissue injury caused by antineoplastic drugs is inhibited by topical dimethyl sulphoxide and alpha tocopherol. Br J Cancer 48: 873–876, 1983.

    Article  PubMed  CAS  Google Scholar 

  42. Emiroglu M, Ercöcen AR, Demirseren ME, et al: Histopathological changes in adriamycin extravasation injury. Ann Plast Surg 41: 103–104, 1998.

    Article  PubMed  CAS  Google Scholar 

  43. Cohen FJ, Manganaro J, Bezozo RC: Identification of involved tissue during surgical treatment of doxorubicin-induced extravasation necrosis. J Hand Surg 8: 43–45, 1983.

    CAS  Google Scholar 

  44. Averbuch SD, Gaudiano G, Koch TH, et al: Doxorubicin-induced skin necrosis in the swine model: protection with a novel radical dimer. J Clin Oncol 4: 88–94, 1986.

    PubMed  CAS  Google Scholar 

  45. Vasilev SA, Morrow C, Morrow CP: Basic fibroblast growth factor in retardation of doxorubicin extravasation injury. Gynecol Oncol 44: 178–181, 1992.

    Article  PubMed  CAS  Google Scholar 

Secondary literature

  1. Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.

    Article  PubMed  CAS  Google Scholar 

  2. Köstering H, Nagel GA: Prophylaxe und Therapie von Zytostatika-Hautnekrosen. Onkologie 6: 317–320, 1980.

    Google Scholar 

  3. Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.

    Article  PubMed  CAS  Google Scholar 

  4. Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6th edition: 1–17, 1999.

    Google Scholar 

  5. Stanley A: Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.

    Google Scholar 

  6. Krämer I: Onkologische Pharmazie. In: Jaehde U, Radziwill R, Mühlebach S, et al (eds) Lehrbuch der Klinischen Pharmazie. Wissenschaftliche Verlagsgesellschaft mbH, 1st edition: 268–269, 1998.

    Google Scholar 

  7. ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 3: 68–69, 1998.

    Google Scholar 

  8. Mullins S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.

    Google Scholar 

  9. Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 109–118, 1994.

    Google Scholar 

  10. Cox RF: Managing skin damage induced by doxorubicin hydrochloride and daunorubicin hydrochloride. Am J Hosp Pharm 41: 2410–2414, 1984.

    PubMed  CAS  Google Scholar 

  11. Rospond RM: Utilization of dimethyl sulfoxide for treating anthracycline extravasation. J Oncol Pharm Practice 1: 33–39, 1995.

    Article  CAS  Google Scholar 

  12. Rudolph R, Larson DL: Etiology and treatment of chemotherapeutic agent extravasation injuries: a review. J Clin Oncol 5: 1116–1126, 1987.

    PubMed  CAS  Google Scholar 

  13. Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.

    Article  PubMed  CAS  Google Scholar 

  14. Kraft A, Weinig S, Edinger M, et al: Anthrazyklin-Extravasate. Der Onkologe 6: 674–686, 2000.

    Article  Google Scholar 

  15. Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 1, 2nd edition: A42–44, 1997.

    Google Scholar 

Further reading

  • Andersson AP, Dahlstrom KK: Clinical results after doxorubicin extravasation treated with excision guided by fluorescence microscopy. Eur J Cancer 29A: 1712–1714, 1993.

    Article  Google Scholar 

  • Barr RD, Benton SG, Belbeck LW: Soft-tissue necrosis induced by extravasated cancer chemotherapeutic agents. J Natl Cancer Inst 66: 1129–1136, 1981.

    PubMed  CAS  Google Scholar 

  • Barr RD, Sertic J: Soft-tissue necrosis induced by extravasated cancer chemotherapeutic agents: a study of active intervention. Br J Cancer 44: 267–269, 1981.

    Article  PubMed  CAS  Google Scholar 

  • Desai MH, Teres D: Prevention of doxorubicin-induced skin ulcers in the rat and pig with dimethyl sulfoxide (DMSO). Cancer Treat Rep 66: 1371–1374, 1982.

    PubMed  CAS  Google Scholar 

  • Diekmann J, Ransom J: Extravasation of doxorubicin from a hickmanTM catheter: a case presentation. Oncol Nurs Forum 12: 50–52, 1985.

    PubMed  CAS  Google Scholar 

  • Disa JJ, Chang RR, Mucci SJ, et al: Prevention of adriamycin-induced full-thickness skin loss using hyaluronidase infiltration. Plast Reconstr Surg 101: 370–374, 1998.

    Article  PubMed  CAS  Google Scholar 

  • Donaldson SS, Glick JM, Wilbur JR: Adriamycin activating a recall phenomenon after radiation therapy. Ann Intern Med 81: 407–408, 1974.

    Article  PubMed  CAS  Google Scholar 

  • Dorr RT, Alberts DS: Failure of DMSO and vitamin E to prevent doxorubicin skin ulceration in the mouse. Cancer Treat Rep 67: 499–501, 1983.

    CAS  Google Scholar 

  • Dorr RT, Alberts DS, Stone A: Cold protection and heat enhancement of doxorubicin skin toxicity in the mouse. Cancer Treat Rep 69: 431–437, 1985.

    PubMed  CAS  Google Scholar 

  • Harwood KV: Treatment of anthracycline extravasation — recommendations for practice. J Clin Oncol 5: 1705, 1987.

    PubMed  CAS  Google Scholar 

  • Harwood KV, Bachur N: Evaluation of dimethyl sulfoxide and local cooling as antidotes for doxorubicin extravasation in a pig model. Oncol Nurs Forum 14: 39–44, 1987.

    PubMed  CAS  Google Scholar 

  • Ignoffo RJ, Tomlin W, Rubinstein E, et al: A model for skin toxicity of antineoplastic drugs: doxorubicin (DOX), mitomycin-C (MMC), and vincristine (VCR). Clin Res 29: 437A, 1981.

    Google Scholar 

  • Laughlin RA, Landeen JM, Habal MB: The management of inadvertent subcutaneous adriamycin infiltration. Am J Surg 137: 408–412, 1979.

    Article  PubMed  CAS  Google Scholar 

  • Loth TS, Eversmann WW: Treatment methods for extravasations of chemotherapeutic agents: a comparative study. J Hand Surg 11A: 388–396, 1986.

    CAS  Google Scholar 

  • Luedke D, Sunwoo Y, Luedke S, et al: Doxorubicin (D) induced soft tissue necrosis: occurrence despite pH manipulation. Proc AACR — ASCO 21: 330, 1980.

    Google Scholar 

  • Okano T, Ohnuma T, Efremidis A, et al: Doxorubicin-induced skin ulcer in the piglet. Cancer Treat Rep 67: 1075–1078, 1983.

    PubMed  CAS  Google Scholar 

  • Preuss P, Partoft S: Cytostatic extravasations. Ann Plast Surg 19: 323–327, 1987.

    Article  PubMed  CAS  Google Scholar 

  • Rudolph R, Suzuki M, Luce JK: Experimental skin necrosis produced by adriamycin. Cancer Treat Rep 63: 529–537, 1979.

    PubMed  CAS  Google Scholar 

  • Schwartsmann G, Sander EB, Vinholes J, et al: N-acetylcysteine protects skin lesion induced by local extravasation of doxorubicin in a rat model. Am J Pediatr Hematol Oncol 14: 280–281, 1992.

    Article  PubMed  CAS  Google Scholar 

  • Seyfer AE, Solimando DA: Toxic lesions of the hand associated with chemotherapy. J Hand Surg 8: 39–42, 1983.

    CAS  Google Scholar 

  • Svingen BA, Powis G, Appel PL, et al: Protection against adriamycininduced skin necrosis in the rat by dimethyl sulfoxide and a-tocopherol. Cancer Res 41: 3395–3399, 1981.

    PubMed  CAS  Google Scholar 

  • Upton PG, Yamaguchi KT, Myers S, et al: Effects of antioxidants and hyperbaric oxygen in ameliorating experimental doxorubicin skin toxicity in the rat. Cancer Treat Rep 70: 503–507, 1986.

    PubMed  CAS  Google Scholar 

  • Vogelzang NJ: “Adriamycin flare”: a skin reaction resembling extravasation. Cancer Treat Rep 63: 2067–2069, 1979.

    Google Scholar 

  • Wolgemuth RL, Myers CA, Luce JK, et al: Doxorubicin extravasation ulceration: animal model development and testing of potential antidotes. Proc AACR 23: 171, 1982.

    Google Scholar 

  • Zweig JI, Kabakow B, Wallach RC, et al: Rational effective medical treatment of skin ulcers due to adriamycin. Cancer Treat Rep 63: 2101–2103, 1979.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria

    Ines Mader MD

  2. SMZ Floridsdorf, Krankenhaus und Geriatriezentrum, Vienna, Austria

    Patrizia E. Fürst-Weger Mag. pharm

  3. Clinical Division of Oncology, Department of Medicine I, University Hospital, Vienna, Austria

    Robert M. Mader DSc

  4. Anstaltsapotheke, Landeskrankenhaus — Universitätskliniken Innsbruck, Austria

    Elisabeth I. Semenitz MD, Mag. pharm

  5. Kaiser-Franz-Josef Hospital, Vienna, Austria

    Robert Terkola PharmD (Head of Pharmacy)

  6. Apotheke LKH-Univ.-Klinikum Graz, Austria

    Sabine M. Wassertheurer Mag. pharm.

Authors
  1. Ines Mader MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrizia E. Fürst-Weger Mag. pharm
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert M. Mader DSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elisabeth I. Semenitz MD, Mag. pharm
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert Terkola PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sabine M. Wassertheurer Mag. pharm.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Wien

About this chapter

Cite this chapter

Mader, I., Fürst-Weger, P.E., Mader, R.M., Semenitz, E.I., Terkola, R., Wassertheurer, S.M. (2003). Doxorubicin. In: Extravasation of Cytotoxic Agents. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3710-9_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-3710-9_22

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-3712-3

  • Online ISBN: 978-3-7091-3710-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation